A Phase 2 interventional study of activated recombinant human factor VII in Congenital Bleeding Disorder, Haemophilia A With Inhibitors and Haemophilia B With Inhibitors, sponsored by Novo Nordisk A/S. Completed at 37 sites in 12 countries. Open to male participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2017-01-12.
Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing recombinant FVIIa in Hemophilia A — 1 open to participants now, 1 under way, none of them phase 3. recombinant FVIIa · Hemophilia A.
Among the 20 studies testing recombinant FVIIa in Hemophilia A, this one is the 11th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2004, is one of 3 in phase 2, and was the 1st registered.
844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.
Browse Hemophilia A studies →1 of the 20 studies testing recombinant FVIIa in Hemophilia A is open now, in 1 country. Recruiting first, the newest first:
American Thrombosis and Hemostasis Network · Sites in United States
Ages 12–100
By country, each count listing its studies:
recombinant FVIIa: first FDA approval 1999 (Novoseven, Novoseven Rt), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →
Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.
This study: 2 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 1 started in 2004.
This study's enrollment of 23 is below the median of 30 across 499 interventional studies indexed under Hemophilia A.
Median enrollment 24 across the 19 interventional studies. Of the 17 that completed or were terminated, 5 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 20 have an industry lead sponsor. The 8 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
92 studies in Hemophilia A by Novo Nordisk A/S: 8 open now, 12 under way, 5 of them phase 3. Of 78 finished, 20 (26%) have results posted.
Among the 92 studies in Hemophilia A by Novo Nordisk A/S, this one is the 42nd largest by enrollment of the 59 interventional ones that give a count, is the only one that started in 2004, is one of 7 in phase 2, and was the 1st registered.
Novo Nordisk A/S’s Hemophilia A studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 20 studies testing recombinant FVIIa in Hemophilia A, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 92 in Hemophilia A:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in Africa, Asia, Europe, South America, and the United States of America (USA).
The purpose of this study is to evaluate the effectiveness of secondary prophylactic treatment with NovoSeven® in haemophilia A and B patients with inhibitors.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Reduction of bleeds
Time frame: During 3 months treatment period as compared to 3 months observation period
Efficacy variables
The record gives a start of Mar 2004, a primary completion of Nov 2005 and a completion of Nov 2005. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Recombinant FVIIa